WALTHAM, Mass., Oct. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that interim data from its randomized, controlled, Phase 2 study of ZYBRESTAT(TM) in combination with Avastin(R) and chemotherapy in patients with advanced non-small cell lung cancer will be presented in a poster session at the upcoming AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston, MA, November 15-18, 2009.
